Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

The annual ranking of innovative power of China's biopharmaceutical enterprises has been released, with HealthGen once again topping the list of China's BigPharma Top 10 in terms of innovation.

Published Time:

2022-09-19

On September 16, 2021, MineNet held an online conference titled "Only Innovators Can Go Farther -- Release of the 2021 Top 100 Innovative Chinese Biopharmaceutical Enterprises Series Rankings," and released the "Top 10 Innovative BigPharma Enterprises in China Ranking," "Top 30 Innovative Small Molecule Drug Enterprises in China Ranking," and other series rankings.

  Among them, the recently released COVID-19 vaccine "Likang V-01" has been included in the emergency use of sequential booster immunization. HealthGen (10.180,  -0.06 ,  -0.59% ) Pharmaceutical Group Co., Ltd. was included in the "Top 10 Innovative BigPharma Enterprises in China Ranking" sub-list of the "2021 Top 100 Innovative Chinese Biopharmaceutical Enterprises Series Rankings".

  Note: HealthGen (including Lizhu Pharmaceutical) is included in the BigPharma list.

  It is reported that this ranking is guided by the ability to implement biopharmaceutical innovation achievements, based on the theoretical basis of the Ministry of Science and Technology's "Evaluation Index System for Enterprise Innovation Ability," and according to the characteristics of the biopharmaceutical industry, the innovation ability evaluation indicators are summarized into four dimensions and 11 indicators: "innovation input," "innovation achievements," "intellectual property rights," and "innovation drive." Combined with the annual reports of innovative pharmaceutical companies, CDE review data, third-party patent statistics agencies, and publicly available data statistics, a comprehensive evaluation of innovative pharmaceutical companies was conducted.

  During this selection process, MineNet organized an expert committee for the "2021 Top 100 Innovative Chinese Biopharmaceutical Enterprises Series Rankings." Referring to international classification methods for biopharmaceutical enterprises, the rankings were divided into four sub-lists: "Top 10 Innovative BigPharma Enterprises in China Ranking," "Top 30 Innovative Small Molecule Drug Enterprises in China Ranking," "Top 30 Innovative Antibody Drug Enterprises in China Ranking," and "Top 30 Innovative New Technology Drug Enterprises in China Ranking".

  Since its establishment, under the leadership of Chairman Zhu Baoguo, HealthGen Pharmaceutical Group has focused on R&D and operation in the field of pharmaceutical innovation. After decades of brand cultivation and R&D accumulation, it has developed into a comprehensive innovative R&D pharmaceutical group covering multiple fields, including chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, and health products.

  According to Wind data statistics, in 2021, the threshold for the top ten pharmaceutical companies in R&D investment was over 900 million yuan. Among the top ten pharmaceutical companies in R&D investment, HealthGen Pharmaceutical Group's two major listed companies, HealthGen and Lizhu Pharmaceutical, had R&D investments of 1.397 billion yuan and 1.146 billion yuan respectively in 2021, with year-on-year growth of 30.36% and 29.59%, ranking sixth and seventh respectively.

  In recent years, HealthGen has firmly implemented a dual-engine driven strategy, focusing on its pharmaceutical main business, actively accelerating the R&D and global layout of innovative drugs and high-barrier complex preparations, and gradually growing into an innovative pharmaceutical enterprise with industry influence. HealthGen adopts a research and development model that combines independent research and development with external introduction and collaborative development, paying attention to cutting-edge technologies and unmet clinical needs; in the layout of the R&D pipeline, HealthGen has chosen a "differentiated" competitive strategy: on the one hand, starting with the R&D of improved new drugs, striving to promote the listing of new products faster and in greater numbers; on the other hand, laying out cutting-edge technologies such as AI drug molecular design and synthetic biology to empower the group's R&D pipeline in terms of innovation, success rate, and efficiency.

  At the beginning of this year, Informa published a white paper, "2022 Pharmaceutical R&D Trend Annual Analysis," which pointed out that the global new drug R&D boom continued in 2022, and China has become an important emerging force in global new drug R&D. In 2021, 47 innovative drugs passed CDE review in China, setting a new historical high, which means that China's pharmaceutical industry's innovation ability and high-quality development have further strengthened, the process of new drug listing is accelerating, and the industry's ability to meet the clinical needs of patients is strengthening.

  The establishment of the "Top 100 Innovative Chinese Biopharmaceutical Enterprises Series Rankings" is an evaluation of China's pharmaceutical (11.940,  -0.27 ,  -2.21% ) creation innovation industry (34.330,  -0.27 ,  -0.78% ) past review and summary, but also a prediction and outlook for the future. The ranking selection has received active participation and high praise from industry experts and scholars, new drug R&D institutions, enterprise R&D managers, entrepreneurs, securities investment institutions, and industry colleagues, demonstrating the good atmosphere of competition and innovation in China's innovative drug industry.